BC Week In Review | May 4, 2018
Clinical News

uniQure reports preclinical data for Huntington's disease candidate

uniQure N.V. (NASDAQ:QURE) reported preclinical data showing that AMT-130 decreased mutant huntingtin (HTT) protein in animal models of Huntington's disease. Data were presented at the American Academy of Neurology meeting in Los Angeles. In a...
BC Week In Review | May 4, 2018
Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million on May 3 in a follow-on through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright &...
BC Extra | May 3, 2018
Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million in a follow-on Thursday through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright & Co. and...
BC Week In Review | Nov 18, 2016
Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
BC Extra | Nov 15, 2016
Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR...
Items per page:
1 - 5 of 5